BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Mitchell et al. generated a ponatinib-resistant CML cell line (KCL22pon-res) and performed RNA-sequencing (RNA-seq) and gene ontogeny (GO) enrichment analysis to detect alternative drug targets in BCR::ABL-independent TKI resistance [151].